Karen G. Krasney
Net Worth

Last updated:

What is Karen G. Krasney net worth?

The estimated net worth of Ms. Karen G. Krasney is at least $3,483,050 as of 13 Dec 2024. She owns shares worth $15,550 as insider and has received compensation worth at least $3,467,500 in null.

What is the salary of Karen G. Krasney?

Ms. Karen G. Krasney salary is $346,750 per year as Executive Vice President, Gen. Counsel & Sec. in null.

How old is Karen G. Krasney?

Ms. Karen G. Krasney is 72 years old, born in 1953.

What stocks does Karen G. Krasney currently own?

As insider, Ms. Karen G. Krasney owns shares in one company:

Company Title Shares Price per share Total value
(CAPR) Executive Vice President, Gen. Counsel & Sec. 2,030 $7.66 $15,550

What does do?

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

CAPR logo
CAPR
$7.66

Karen G. Krasney insider trading

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 8,000 $1.39 $11,120
Option
Stock Option (Right to Buy) 5,000 $1.39 $6,950
Option
Common Stock 18,932 $1.39 $26,315
Option
Stock Option (Right to Buy) 18,932 $1.39 $26,315
Purchase
Warrants (Right to Buy) 2,030 $4.5 $9,135
Purchase
Common Stock 4,060 $2.4 $9,744
Purchase
Common Stock 7,096 $3.52 $24,999

key executives

executives and other stock owners filed with the SEC:

  • Dr. Frank Isaac Litvack FACC, M.D. (69) Executive Chairman
  • Dr. Linda Marbán (62) Co-Founder, Pres, Chief Executive Officer & Director
  • Mr. Anthony J. Bergmann M.B.A. (39) Chief Financial Officer & Corporation Treasurer
  • Ms. Karen G. Krasney (72) Executive Vice President, Gen. Counsel & Sec.